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Review Article
AbstractThe poor efficacy of many cancer chemotherapeutics, which are often non-selectiveand highly toxic, is attributable to the remarkable heterogeneity and adaptability ofcancer cells. The Warburg effect describes the up regulation of glycolysis as themain source of adenosine 5’-triphosphate in cancer cells, even under normoxicconditions, and is a unique metabolic phenotype of cancer cells. Mitochondrialsuppression is also observed which may be implicated in apoptotic suppressionand increased funneling of respiratory substrates to anabolic processes, conferringa survival advantage. The mitochondrial pyruvate dehydrogenase complex issubject to meticulous regulation, chiefly by pyruvate dehydrogenase kinase. At theinterface between glycolysis and the tricarboxylic acid cycle, the pyruvatedehydrogenase complex functions as a metabolic gatekeeper in determining thefate of glucose, making pyruvate dehydrogenase kinase an attractive candidate in abid to reverse the Warburg effect in cancer cells. The small pyruvatedehydrogenase kinase inhibitor dichloroacetate has, historically, been used inconditions associated with lactic acidosis but has since gained substantial interestas a potential cancer chemotherapeutic. This review considers the Warburg effectas a unique phenotype of cancer cells in-line with the history of and currentapproaches to cancer therapies based on pyruvate dehydrogenase kinaseinhibition with particular reference to dichloroacetate and its derivatives.
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1. IntroductionEnergy production in cells can occur relativelyinefficiently via glycolytic conversion of glucose topyruvate in the cytosol. Alternatively, much moreefficient energy production can arise via the conversionof pyruvate to acetyl-Coenzyme A (acetyl-CoA) and thesubsequent tricarboxylic acid (TCA) cycle in themitochondria. Cancer cells tend to utilize the formerpathway more than normal cells. This shift of energyproduction away from the mitochondria to the glycolyticpathway is referred to as the 'Warburg effect' after itsproposer Otto Heinrich Warburg.1 Reversing theWarburg effect, thereby shifting energy production backto the mitochondria and potentially reinstatingmitochondrial apoptotic pathways, has become anattractive potential treatment for cancer in recent years.A particularly attractive therapeutic target in thisrespect is the enzymatic activity of the mitochondrialpyruvate dehydrogenase complex (PDC) which sits atthe interface between glycolysis and the TCA and,
therefore, regulates the metabolic fate of glucose downone or the other pathway.PDC catalyzes the irreversible oxidative decarboxylationof pyruvate to acetyl-CoA via a sequential mechanism(Figure 1). This acetyl-CoA, along with the acetyl-CoAfrom fatty acid β-oxidation, enters the TCA cycle toproduce the electron donors NADH and FADH2. Theelectron transport to molecular oxygen via respiratorychain complexes then leads to the formation of a protongradient across the inner mitochondrial membrane. Theelectrochemical potential energy within this protongradient is utilized to drive the formation of ATP viamitochondrial ATP synthetase.The PDC contains multiple copies of three differentcatalytic components. The E1, pyruvate dehydrogenase,component (pink) catalyzes the decarboxylation ofpyruvate to hydroxyethyl-TPP and, subsequently, thereductive acetylation of lipoyl moieties on the E2,
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dihydrolipoamide acetyltransferase, component (blue).The E2 component then transfers these acetyl groups toCoA to form acetyl-CoA. The E3, dihydrolipoamidedehydrogenase, component (green) utilizes a FADprosthetic group to catalyze the oxidation of the reducedlipoyl moieties on the E2 component with theconcomitant reduction of NAD+.Situated within the mitochondrial matrix, PDC is a highlyintegrated multimeric enzyme complex containingmultiple copies of three different catalytic moleculesthat, collectively, catalyze the sequential oxidativedecarboxylation of pyruvate (Figure 1).4 First, thepyruvate dehydrogenase (E1) component catalyzes thedecarboxylation of pyruvate to hydroxyethyl-thiaminepyrophosphate (hydroxyethyl-TPP) followed by thereductive acetylation of lipoyl moieties on thedihydrolipoamide acetyltransferase (E2) component.The latter component then transfers the acetyl moietiesto CoA to form acetyl-CoA. Finally, the dihydrolipoamidedehydrogenase (E3) component, utilizing its FADprosthetic group, catalyzes the oxidation of the reducedlipoyl moieties on the E2 component with theconcomitant reduction of NAD+.
2. Pyruvate dehydrogenase complex E1α
regulationAt such a crucial and central position within normalcellular metabolism, the catalytic activity of PDC is
subject to meticulous regulation with many mechanismsacting in concert including: allostery; reversiblephosphorylation; reversible acetylation; and reversiblesuccinylation (Figure 2). These post-translationalmodifications are, in turn, themselves regulatedcontributing to the elaborate regulation of carbon fluxthrough the PDC.The principal regulation of mammalian PDC is achievedthrough the site-specific, inhibitory phosphorylation ofthe α subunits of the heterotetrameric (α2β2) E1component at three different sites — Ser293 (site 1),Ser300 (site 2), and Ser232 (site 3).5 The presence ofthree different phosphorylation sites confers a level ofcomplexity to PDC regulation and allows fine-tuning tometabolic requirements achieved through the activitiesof pyruvate dehydrogenase kinase (PDK) and pyruvatedehydrogenase phosphatase (PDP). However, it hasbeen shown, through site-directed mutagenesis, thatphosphorylation at any one site of the E1 componentleads to inhibition of the catalytic component.6Site-specific phosphorylation of E1α results in E1inactivation via different mechanisms; for example,phosphorylation of site 1 prevents steric interaction ofreaction substrates with the E1 active site, whereas site3 phosphorylation affects co-enzyme, TPP, binding toE1.7, 8 Additionally, phosphorylation of E1α at Tyr301blocks binding of substrate (pyruvate), therebyinhibiting the catalytic component in a similar manner toSer293phosphorylation.9
Figure 1: The catalytic mechanism of the pyruvate dehydrogenase complex (adapted2,3). The PDC contains multiple copies ofthree different catalytic components. The E1, pyruvate dehydrogenase, component (pink) catalyzes the decarboxylation ofpyruvate to hydroxyethyl-TPP and, subsequently, the reductive acetylation of lipoyl moieties on the E2, dihydrolipoamideacetyltransferase, component (blue). The E2 component then transfers these acetyl groups to CoA to form acetyl-CoA. The E3,dihydrolipoamide dehydrogenase, component (green) utilizes a FAD prosthetic group to catalyze the oxidation of the reducedlipoyl moieties on the E2 component with the concomitant reduction of NAD+.
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Figure 2: Mechanisms involved in decreasing PDC activity. (A) PDK1 is phosphorylated on Tyr243 leading to increasedphosphorylation of the PDC E1α subunit at Ser293, Ser300, or Ser232. (B) The PDC E1 subunit can also be phosphorylatedby multiple oncogenic tyrosine kinases on Tyr301 which blocks pyruvate substrate binding. (C) Tyr381 phosphorylation ofPDP1 induces ACAT1 recruitment which subsequently acetylates PDP1 at Lys202, causing its deactivation, and the PDC E1subunit at Lys321 promoting PDC association with PDK1 and the subsequent phosphorylation of the former. (D) PDP1phosphorylation at Try94 reduces its affinity for the PDC E2 subunit and, therefore, inhibits dephosphorylation of the latter.(E) Cancer cells may display decreased expression of SIRT3 which leads to increased acetylation of the PDC E1 subunit atLys321. (F) Oncogenic phosphorylation of PDK1 at Tyr136, Tyr243 or Tyr244 leads to increased phosphorylation of the PDCE1 subunit at Ser293, Ser300, or Ser232.
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Figure 3: The structures of PDK inhibitors with potential for the treatment of cancer. (A) Mito-DCA is a DCA derivative whichincorporates a lipophilic triphenylphosphonium cation linked to the DCA-derivative PDK inhibiting part of the molecule (bothhighlighted). (B) Mitaplatin is a fusion of a six-coordinate platinum (IV) complex synthesized from the widespreadchemotherapeutic cisplatin, with two DCA moieties in the axial positions. (C) PS10 is based on the structure of the PDKATP-binding pocket and is derived from a known Hsp90 inhibitor with a key substitution of the carbonyl group, linking theresorcinol and isoindoline moiety of the molecule, to a sulphonyl group. (D) Compound 11a is structured on a4,5-diarylisoxazole-based Hsp90 inhibitor and is a 3-amide substituted isooxazole derivative.
2.1 Pyruvate dehydrogenase kinasesPDKs are serine-specific protein kinases which areintimately associated with the PDC through binding tothe lipoyl domains of E2. These heterodimeric kinasesare unrelated to cytoplasmic Ser/Thr/Tyr kinases andare composed of a catalytically active α-subunit and aregulatory β-subunit; the α-subunit is composed of eightsub domains, all of which are critical for the correctbinding and orientation of ATP.10 Four mammalianisoforms of PDK differentially phosphorylate the specificserine residues of the PDC, conferring additionalcomplexity to PDC regulation; PDK1 can phosphorylateall three sites, whilst PDK2, PDK3, and PDK4, canphosphorylate sites 1 and 2only.11PDKs are subject to acute, allosteric stimulation by thereaction products of PDC (NADH and acetyl-CoA) byreduction of lipoyl moieties on the E2 lipoyl domains ofE5. Reactant availability, namely pyruvate and ADP,promotes PDK inhibition and a combination of theseeffectors act synergistically.12 It follows thatproduct/reactant ratios determine PDK activity by theproportion of active PDC (dephosphorylated) to inactivePDC (phosphorylated).
PDK1 may be regulated by oncogenic tyrosinephosphorylation such as that by oncogenic fibroblastgrowth factor receptor 1. It has been demonstrated thatPDK1 may be phosphorylated on at least three differenttyrosine residues by tyrosine kinases (Tyr136, Tyr243,and Tyr244), which increases ATP binding affinitytoward the active site and promotes association withPDC.13 Increased efficiency of PDK1 means that E1α isinactivated by phosphorylation more efficiently by thisoncogenic tyrosine kinase stimulation of PDK1.
2.2 Pyruvate dehydrogenase phosphatasesPDPs are heterodimeric enzymes composed of acatalytic and a regulatory subunit with two isoforms ofthe catalytic subunit identified in mammalian tissues;PDP1 and PDP2. Both PDP isoforms require Mg2+ forcatalysis with PDP1 activity being more sensitive tocellular Mg2+ concentration than PDP2. PDP1 binds tothe L2 domain of the PDC E2 subunit, facilitated by Ca2+playing a ‘bridging role’5 — thus, cellular Ca2+concentration regulates PDP1 activity and, in turn, PDCactivity. PDP2 binding to a lipoyl domain of E2 has notbeen detected and the isoform is not sensitive to Ca2+,
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though does require a higher concentration of Mg2+ thanPDP1 for catalysis. Both PDP isoforms are capable ofdephosphorylating each serine site and thus reactivatingthe PDC, though with diminutive variance in theiractivities for each site; in the order site 2 > site 3 > site1.14Like PDKs, PDPs may be regulated by oncogenic tyrosinekinases such as ABL and JAK2. For example, Tyr94phosphorylation on PDP1 reduces binding ability tolipoic acid of the E2 component of the PDC and thereforedecreases association of PDP with PDC.15
2.3 Acetylation and succinylationAcetylation of lysine residues constitutes a novelpost-transcriptional modification which may rivalphosphorylation as a major regulator of many, if not all,metabolic pathways.16 A number of lysine acetylationsites have been identified on PDC E1α in cancer cells,which complement the phosphorylation-mediatedregulation of the PDC.17 The acetylation status of PDCE1α influences activity of the complex due to theinteractions of lysine acetylation sites with PDKs andPDPs. The mitochondrial acetyltransferase ACAT1 andthe mitochondrial deacetylase sirtuin 3 (SIRT3) havebeen implicated in this respect.18 In normal,differentiated cells, PDC is active with E1α beingassociated with PDP1 and SIRT3. However, cancer cellsdemonstrate inactive PDC with E1α associated withPDK1. In this oncogenic process, Y381 phosphorylationcauses the dissociation of SIRT3 and the recruitment ofACAT1. Acetylation of PDP1 and E1α by ACAT1 causesthe dissociation of PDP1 and the recruitment of activePDK1, with a subsequent phosphorylation event byPDK1 to render the PDC inactive. Furthermore, manyhuman cancers are associated with a SIRT3 deficiency,and mice deficient in SIRT3 have been shown tospontaneously develop breast cancer.18Reversible succinylation also constitutes apost-transcriptional modification of metabolic enzymesand a number of lysine succinylation sites have beenidentified on the E1α, E1β, E2, and E3 subunits of PDC.19,
20 Most of the succinylation sites do not overlap with theaforementioned acetylation sites, suggesting divergentregulatory mechanisms. Indeed, SIRT5 has been shownto negatively regulate PDC by means of succinylation,suppressing the enzyme’s metabolic role.19
2.4 Transcriptional regulationIn addition to the post-transcriptional regulation of PDC,long-term regulation of the enzyme complex may beachieved via transcriptional control. Indeed, in a numberof disease, endocrine and nutritional states, the activityof PDC has been shown to be regulated by the ratio ofPDKs and PDPs determined at the transcriptional level.21In the context of cancer, PDK1 expression has beenshown to be upregulated by the oncogeneshypoxia-inducible factor-1 (HIF-1 and c-Myc which
inactivate PDC by phosphorylation to essentially achieveglobal inhibition of the complex and, therefore, define anoxidative metabolic profile.22
3. TheWarburg effect and cancer
metabolismThe heterogeneity and adaptability of cancer cellspresents immense challenges in cancer treatment andchemotherapeutic targeting of cancer cells hastraditionally been non-specific, affecting cellularprocesses or components essential to normal cells. Theidentification of pathways, phenotypes, or genotypesunique to cancer cells may drastically improve prospectsfor efficacious, selective treatments. However, molecularcharacteristics of even histologically identical cancersprove highly dissimilar, even within the same tumour.23Under normal, aerobic, physiological conditions, cellsmeet their energy requirements by the production ofATP in the mitochondria via oxidative phosphorylation.Alternatively, under hypoxic conditions, normal cellsderive their ATP from the conversion of glucose tolactate. The Pasteur effect describes the cell-autonomousadaptation of most mammalian cells to the presence ofoxygen, characterized by a decreased rate of glycolysisand an increased rate of oxidative phosphorylation.24 Indirect contradiction, Warburg observed that cancer cellsshift to aerobic glycolysis as the main source of ATP,with an associated increased uptake of glucose andenhanced lactate production, even under normoxia.1These seminal findings were confirmed by a number ofdifferent researchers which extended Warburg’s in vitromodel into in vivo models, though a number of studiesmay be questionable.25,26 For example, in a studyinvestigating glucose utilization of a Novikoff hepatoma,it was concluded that lactate production was four timeshigher than in normal liver cells. However, the glycolyticcontribution of ATP could not be deduced in this studyas oxygen consumption was not measured and,therefore, did not constitute a valid reflection of totaloxidative ATP production.27Warburg later proposed that tumour cells possess anintrinsic defect of oxidative metabolism, explaining theobserved increased glycolytic flux as a compensatorymechanism.28 Whilst research has repeatedly, thoughoften questionably, shown increased aerobic glycolysisin many tumour cell types, a metabolic defect of cancercells has not been established. Rather, research supportsthe existence of both a functional TCA cycle andpronounced aerobic glycolysis, demonstrating a priorityof metabolic activity for biosyntheses as opposed tocomplete glucose oxidation.29 Although the phenomenonis not universal to all cancer types30, it is sufficiently wellestablished that it often forms the basis for cancerdiagnostics using the glucose analogue tracer18fluorodeoxyglucose in tandem with positron emissiontomography (FDG-PET)31, though there are a number of
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established factors which may confound results such asglucose concentration, tissue density, and fibrosis32.However, the assumption that FDG-PET functions on thebasis of increased aerobic glycolysis specifically appearsto be unreasoned.Because aerobic glycolysis is much less efficient thanoxidative phosphorylation at generating ATP, cancercells upregulate glucose receptor and glycolytic enzymegene transcription in a bid to compensate for thisinefficiency and meet their increasing ATP demands.This metabolic profile also favours the reducedfunneling of metabolic intermediates to oxidativecatabolism within the mitochondria and, instead, towardanabolic processes.33 The accumulation of bothglycolytic and TCA cycle intermediates has been shownto enhance cancer malignancy by the promotion ofangiogenesis, adaptability to hypoxic conditions,metastasis, and immune-evasion.34 Thus, the Warburgeffect provides benefits to both cell bioenergetics andbiosyntheses. Accordingly, increased glucose uptake andhigh lactate levels are correlated with poor cancerpatient prognosis and increased tumouraggressiveness35, 36, though it is important to considerthat the Warburg phenotype is not unique to cancercells, but is also observed in non-cancer cells duringrapid proliferation.37The Warburg metabolic phenotype occurs early intumourigenesis. It has been proposed that tumour cellsmust rely on anaerobic glycolysis as a primary ATPsource in the hypoxic microenvironment during earlytumourigenesis38; the transient hypoxia of a developingtumour mass cannot meet oxygen demands to carry outoxidative metabolism due to local vasculaturerestrictions. Tumour cells may evade hypoxia-mediatedcell death by the mutation or decreased expression of
p53.39 The up regulation of glycolysis is achieved via thehypoxic induction of HIF-1 which stimulates key steps inglycolysis whilst also regulating genes controllingangiogenesis, cell survival, and cell invasion. HIF-1 is aheterodimer of a constitutively expressed HIF-1βsubunit and a regulated HIF-1α subunit. Under normoxicconditions, HIF-1 is rapidly degraded via theubiquitin-proteasomal pathway; HIF prolyl hydroxylaseshydroxylate Pro402 and Pro564 of HIF-1α promotingassociation of HIF-1 with the tumour suppressor proteinVon Hippel-Lindau (pVHL) which acts as a ubiquitinligase substrate recognition component of an E3ubiquitin ligase.40 The response to hypoxia is, in part,mobilized by the activation of HIF-1 by preventing itsdegradation; this mediates a switch from oxidative toglycolytic metabolism by regulating expression of manyglycolytic enzymes, glucose transporters, andmitochondrial enzymes.41 HIF-1 also activates thetranscription of genes controlling angiogenesis,erythropoiesis, cell survival, and cell migration42 whichcan amplify malignant progression. However, thestabilization of HIF-1 may also be observed under
normoxic conditions suggesting that other factors, suchas hormones, growth factors, or oncogenes, may causeHIF-1 stabilization and promotion of the glycolyticphenotype.43 One of the most common molecularabnormalities, loss of p53, directly induces pyruvatedehydrogenase kinase expression and enhances HIF-1αtranscription and stability.44,45 Alternatively, mutationsin tumour suppressor VHL may result in the constitutiveactivation of HIF-1α. The collective action of manyoncogenes may emit “pseudo-hypoxic” signalsestablishing a feed-forward feedback loop to sustain theglycolytic phenotype.In addition to the up regulation of glucose, HIF-1 hasbeen shown to enhance expression of PDK1.46 Bydiverting pyruvate towards glycolysis, the tumour cellmitochondria are essentially deprived of their “fuel”which, therefore, suppresses mitochondrial activity,concomitantly enhancing apoptotic resistance.Mitochondria-mediated apoptosis depends on the effluxof pro-apoptotic mediators, such as cytochrome c, fromthe mitochondria through the voltage- and redox-gatedmitochondrial permeability transition pore (MPTP). TheMPTP is a megachannel which includes thevoltage-dependent anion channel (VDAC), requiringsignificant mitochondrial depolarization for opening.47Suppressed mitochondrial function promoteshyperpolarization of the mitochondrial membrane and adecrease in the generation of reactive oxygen species48;both of which contribute to an increase in the openingthreshold required for the MPTP, which suppressesapoptosis and, again, promotes tumour growth. Thesuppression of mitochondria can also stabilize HIF-1α.This is because the TCA cycle product α-ketoglutarate, arequired co-factor for HIF-1α destabilization by prolylhydroxylases, is decreased.49Whilst the notion of HIF-1α stability has muchsupporting evidence, some cancers demonstrateglycolytic metabolism before exposure to hypoxia.Leukaemic cells, for example, are subject to higheroxygen concentrations than cells of other tissues yet arehighly glycolytic.50In summary, the fate of glucose in metabolism is largelydependent on the gate-keeper pyruvate dehydrogenasecomplex at the interface of glycolysis and the TCA cycle.To stress the importance of PDC activity, replacingendogenous PDK1 with a mutated form in which thephosphorylated tyrosine residues are mutated, causes ashift in the metabolic profile of cancer cells towardoxidative metabolism; suggesting a reversion of theWarburg effect.13 This warrants PDC, and particularlyPDK, of great interest in the potential therapeuticreversion of the cancer cell Warburg effect as a means ofcancer therapy.
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4. Therapeutic targeting of pyruvate
dehydrogenase kinase in cancer
4.1 DichloroacetateDichloroacetate (DCA) is a small, 150 Da,well-established inhibitor of PDK which can penetratemost tissues following oral administration, including thecentral nervous system, entering cells via themonocarboxylate and pyruvate carrier systems andconcentrating in the mitochondria.51 In adose-dependent fashion, DCA inhibits PDK atconcentrations of 10-250 µM subsequently activatingPDH.52 PDK isoforms have a mostly conserved pocket towhich DCA binds; PDK2 is the most ubiquitouslyexpressed isoform and is most sensitive to inhibition byDCA.53 In PDK2, DCA occupies the same binding site aspyruvate; the carboxylate group of DCA forms asalt-bridge with Arg154 in the N-terminal domain of theenzyme, with the chlorine atoms residing in ahydrophobic region of the pocket.54 Suppression ofPDK2 expression using siRNA mimics the action of DCA,thereby confirming inhibition of the enzyme as themajor pharmacodynamic mechanism of DCA.55Historically, DCA was used for ameliorating thesymptoms of lactic acidosis associated with a number ofcongenital mitochondrial diseases in children.56 Over thepast few decades, chronic DCA administration has beenclinically tested in adults and children in a number ofdisease states associated with lactic acidosis includingdiabetes mellitus and pulmonary arterialhypertension.57-59 More recently, the clearanti-neoplastic activity of DCA has been extensivelystudied in a number of investigations involving differenttissues including those from prostate cancer60,endometrial cancer61 and breast cancer62. In fact, in vivostudies have demonstrated the reversion of anaggressive metastatic breast cancer corroborate withthe anti-neoplastic activity of DCA.62 However, thepublished research sometimes reports contradictory in
vitro and in vivo effects.63The activation of PDC by means of DCA inhibition of PDKcauses an increased carbon flux through PDC and anincreased mitochondrial production of NADH. Theelectron-donor NADH is a substrate ofelectron-transport chain (ETC) complex-I, and thus leadsto an increased production of reactive oxygen species(ROS).64 Furthermore, it has been proposed thatincreased ROS production may lead to oxidative damagein the ETC causing restricted mitochondrial protonefflux, in turn causing a decrease in membranepotential.55 As discussed earlier in this article,hyperpolarization of the mitochondrial membrane ispartly responsible for the suppression of mitochondrialfunction in cancer cells. Through the sustainedcomplex-I generation of ROS, significantly decreasedmitochondrial membrane potential allows the openingof the voltage-sensitive MPTP, allowing efflux of
pro-apoptotic proteins such as cytochrome c andinitiation of apoptosis via caspase activation.Additionally, through the generation of ROS, DCAessentially reverses the “pseudo-hypoxic” phenotype ofcells in vivo by inhibition of PDK65 and suppressesnormoxic activation of HIF-1α. Increased ROS alsoincrease the activity of redox-sensitive tumoursuppressors such as p53 which, in tandem withα-ketoglutarate, lead to decreased stabilization ofHIF-1α66. Whilst the ROS-mediated induction ofapoptosis is generally accepted as the leadingmechanism of DCA action, cell cycle arrest and theinduction of autophagy have been demonstrated inhuman colorectal and prostate carcinoma cell lines, andHT29 tumour xenografts following DCA treatment.67 Itshould, however, be noted that the in vitro results insome of these studies are somewhat questionable from aphysiological point of view due to the highconcentrations of DCA used (75–100 mM).In a clinical trial of five patients with glioblastomamultiforme, an eclectic combination of DCA,temozolomide, radiation, and surgery were used in thetreatment regime.68 With an emphasis on ex vivoanalyses of tumour cells, the authors demonstratedchanges to the mitochondrial membrane potential,increased levels of mitochondrial ROS, and increasedapoptosis. Further investigations revealed suppressedHIF-1α expression, enhanced p53 activation anddecreased angiogenesis both in vitro and in vivodemonstrating the multitude of downstream effects ofPDK inhibition. One patient with recurrent disease diedfrom complications of brain oedema three months afterstarting DCA therapy while the remaining four of the fivepatients showed promising results.Many of the concerns raised over potential patienttoxicity of DCA are based on data obtained from in vitroor in vivo studies in which DCA doses administered weremany orders of magnitude higher than those to whichhumans are exposed in treatments. Our patienttolerability knowledge of DCA dosing generally comesfrom publications investigating the drug as a treatmentfor individuals with mitochondrial-linked lactic acidosis.Specifically, DCA has been used to treat olderadolescents and adults (mean age at study entry; 30years) with the common A3243G mutation inmitochondrial DNA that gives rise to the syndrome ofmitochondrial encephalomyopathy, lactic acidosis andstroke-like episodes (MELAS).69 Unfortunately, using atwice daily dose of 12.5 mg / kg, the study had to beterminated prematurely because of an undue incidenceof worsening or new onset peripheral neuropathy. Alater study examined the same dosing regime in youngerchildren (mean age at study entry; 5.6 years) withcongenital lactic acidosis (CLA).51 In contrast to theearlier study in older patients, the authors concludedthat there was good tolerability of DCA and nosignificant differences in the severity or frequency of
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adverse events between the drug and placebo groupsover a six month treatment period. However, the samegroup subsequently showed that, after long term drugtreatment (10 years) some significant worsening inperipheral neuropathy was observed in the DCA-treatedcohort.70 Interestingly, the rate of adverse effect onsetseems directly related to patient age with adults andyoung adolescents being more rapidly affected thanchildren. Accordingly, DCA plasma clearance has beenshown to be inversely associated with age in humans.71In summary, DCA does seem to exhibit some detrimentaleffects in humans in terms of peripheral neuropathy.However, given that the above studies concluded thatthese effects were largely reversible following cessationof drug treatment and the fact that many currentchemotherapeutic drugs cause similar effects, perhapsthis is a relatively small price to pay for the use of DCA incancer treatment.The clinical history of DCA warrants its furtherinvestigation as a cancer monotherapy by targeting afundamental and unique property of many cancer cells,giving an apparent, selective reversal of the Warburgmetabolic phenotype. However, given the metabolic andapoptotic effects of DCA, it could be given concurrentlywith other chemotherapeutics to potentially increasetheir effectiveness or reduce required dosages, therebylimiting toxicity.72 Accordingly, co-treatment with DCA,tamoxifen and omeprazole displayed a synergisticenhancement of anti-tumour activity.73 Whilstchemotherapy resistance is a notorious characteristic ofmany cancers, 5-fluorouracil (5-FU) resistant hypoxicgastric cancer cells were successfully re-sensitized byco-treatment with DCA and 5-FU.74 Similarly, thecombination of the same two drugs has been shown toexert a synergistic anti-tumour effect in colorectalcancer.75 The success of DCA as a monotherapy and intandem with many alternative chemotherapeutics hasbeen exploited by chemical modifications and directconjugation of DCA with several chemotherapeutics.
4.2 Dichloroacetate derivatives and other
pyruvate dehydrogenase kinase inhibitorsMito-DCA (Figure 3A) is a DCA derivative whichincorporates a lipophilic triphenylphosphonium cationthrough a biodegradable linker.76 This incorporationpurports to enhance the potency and cancer cellspecificity of DCA by three orders of magnitude. Whilstappearing to have no significant metabolic effects onnormal cells, Mito-DCA did cause a reversion of theWarburg effect and induction of apoptosis in cancer cellswith dysfunctional mitochondria.Mitaplatin (Figure 3B) is a fusion of a six-coordinateplatinum (IV) complex synthesized from the existingchemotherapeutic cisplatin, with two DCA moieties inthe axial positions.77 Once within the cell, mitaplatindissociates into its respective molecules due to thenegative intracellular redox potential; cisplatin targets
the nucleus where it forms intra-strand nucleotidecrosslinks, whilst DCA targets the mitochondriareversing the Warburg effect and promoting apoptosis.In a number of different cancer cell lines, mitaplatin hasproven to exceed the efficacy of cisplatin alone.77Interestingly, mitaplatin has also proven to be moreefficacious than in studies where DCA and cisplatin wereco-administered but as separate entities.78 This maypermit the administration of a lower effective dose ofMitaplatin than when either of the separate compoundsare employed thereby alleviating some of the peripheralneurotoxicity side effects associated with these drugs.PS10 (Figure 3C) is highly specific PDK inhibitor basedon the structure of the PDK ATP-binding pocketconserved amongst the GHKL ATPase/kinasesuperfamily which also includes heat-shock protein 90(Hsp90). PS10 was derived from a known Hsp90inhibitor to form a highly specific PDK inhibitor with akey substitution of the carbonyl group, linking theresorcinol ring and isoindoline moieties of the molecule,to a sulphonyl group.79 In vivo studies with PS10demonstrated significantly greater PDC activity levels,supporting inhibition of PDK as the mode of action of themolecule and its potential usage in reversal of theWarburg effect. Another structure-guided developmentof a highly specific PDK inhibitor, based on theconserved ATP-binding pocket, is compound 11a (Figure3D) which is structured on a 4,5-diarylisoxazole-basedHsp90 inhibitor and is a 3-amide substituted isoxazolederivative.80 The dual inhibition of Hsp90 and PDC mayprovide some advantage as a cancer therapeutic, thoughit is important to consider similarities ofnucleotide-binding pockets in other kinases which mayresult in unwanted cytotoxic effects.
5. Conclusions and future directionsWarburg’s work did not translate into cancer therapiesfor many decades as it was long believed that the uniquemetabolic phenotype of cancer cells was a consequenceof, but not a major contributor to or cause of, cancer.However, metabolic oncology is now a thriving field inthe battle against cancer.The number of cancer types and the experimentsemployed to date are too limited to make generalizedconclusions on the efficacy of DCA in cancer therapy.DCA has a tremendous clinical profile in the therapeuticmetabolic modulation of mitochondrial diseases and hasproven a promising cancer therapy in a number ofstudies from the past decade. This warrants thoroughexploration into DCA and its derivatives as means ofattaining higher efficacy and reduced toxicity incombination therapies with current, standard cancertreatments which are often non-selective for cancerouscells. Perhaps the fact that investigations into DCA arestagnating is due to the intrinsic generic nature of DCA,meaning it cannot be patented. This creates financial
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barriers to truly exploiting the clinical efficacy of thedrug in cancer therapy.
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